GALECTIN THERAPEUTICS INC Form 8-K November 22, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

November 18, 2011

Date of Report (Date of earliest event reported)

GALECTIN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

NEVADA 000-32877 04-3562325

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

(State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)
7 WELLS AVENUE

NEWTON, MASSACHUSETTS

02459

(Address of principal executive offices) (Zip Code)

(617) 559-0033

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

Item 8.01. Other Events.

In the Form 10-Q Quarterly Report that Galectin Therapeutics Inc. filed on November 10, 2011, we reported that a dispute arose after the settlement agreement was executed with Custom Equity Research, Incorporated (d/b/a Summer Street Research Partners). Following a hearing, the court enforced the settlement agreement upon the terms and for the amount the parties originally negotiated, and both the lawsuit and FINRA arbitration were dismissed with prejudice on November 18, 2011.

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Galectin Therapeutics Inc.

By: /s/ Anthony D. Squeglia Anthony D. Squeglia Chief Financial Officer

Date: November 22, 2011